ArticleInfection and immunity2002
Differential persistence among genomovars of the Burkholderia cepacia complex in a murine model of pulmonary infection.
Article in Infection and immunity, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Long-term lung infection suppression in a mouse model caused via the clinical isolate of Burkholderia cenocepacia using the non-traditional antibacterial agent Fluorothiazinone.The Journal of antibiotics · 2026Article
- Genomic analysis of prophages from Burkholderia gladioli exposes extensive genetic diversity.BMC genomics · 2026Article
- A flagella-dependentmBio · 2025Article
- Article
- Immunization and Immunotherapy Approaches againstVaccines · 2021Review
- Activity of Aerosolized Levofloxacin against Burkholderia cepacia in a Mouse Model of Chronic Lung Infection.Antimicrobial agents and chemotherapy · 2020Article
- Phylogeographic, genomic, and meropenem susceptibility analysis of Burkholderia ubonensis.PLoS neglected tropical diseases · 2017Article
- AnFrontiers in microbiology · 2017Article
- The art of persistence-the secrets to Burkholderia chronic infections.Pathogens and disease · 2016Review
- Colony morphology variation of Burkholderia pseudomallei is associated with antigenic variation and O-polysaccharide modification.Infection and immunity · 2015Article
- Aerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections.Antimicrobial agents and chemotherapy · 2014Article
- Identification of potential diagnostic markers among Burkholderia cenocepacia and B. multivorans supernatants.Journal of clinical microbiology · 2010Article
- Article
- Induction of immune response to the 17 kDa OMPA Burkholderia cenocepacia polypeptide and protection against pulmonary infection in mice after nasal vaccination with an OMP nanoemulsion-based vaccine.Medical microbiology and immunology · 2010Article
- Identification of Burkholderia cepacia complex bacteria with a lipopolysaccharide-specific monoclonal antibody.Journal of medical microbiology · 2010Article
- Virulence and cellular interactions of Burkholderia multivorans in chronic granulomatous disease.Infection and immunity · 2009Article
- Pulmonary bacterial pathogens in cystic fibrosis patients and antibiotic therapy: a tool for the health workers.International archives of medicine · 2008Article
- Development of Galleria mellonella as an alternative infection model for the Burkholderia cepacia complex.Infection and immunity · 2008Article
- A LysR-type transcriptional regulator in Burkholderia cenocepacia influences colony morphology and virulence.Infection and immunity · 2008Article
- Nasal immunization with Burkholderia multivorans outer membrane proteins and the mucosal adjuvant adamantylamide dipeptide confers efficient protection against experimental lung infections with B. multivorans and B. cenocepacia.Infection and immunity · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cystic fibrosis patients infected with strains from different genomovars of the Burkholderia cepacia complex can experience diverse clinical outcomes. To identify genomovar-specific determinants that might be responsible for these differences, we developed a pulmonary model of infection in BALB/c mice. Mice were rendered leukopenic by administration of cyclophosphamide prior to intranasal challenge with 1.6 x 10(4) bacteria. Five of six genomovar II strains persisted at stable numbers in the lungs until day 16 with minimal toxicity, whereas zero of seven genomovar III strains persisted but resulted in variable toxicity. We have developed a chronic pulmonary model of B. cepacia infection which reveals differences among genomovars in terms of clinical infection outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.